L'intérêt à découvert pour Theratechnologies donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Theratechnologies. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Theratechnologies (NASDAQ:THTX) Stock, Rapport sur les intérêts à découvert

Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Theratechnologies Inc

Actor Jim Belushi compared the similarities of acting and cannabis to an audience at the<a href="https://www.benzinga.com/events/cannabis-conference/"> Benzinga Cannabis Capital Conference on Oct. 9.</a>
Here's a look at what makes the two sectors similar and more on Belushi's journey to help people through cannabis.
Acting to Cannabis: Belushi may be best known for his roles in television and movies, but at the 2024 Benzinga Cannabis Capital Conference, the audience and other speakers are aware of his efforts in <a href="https://www.benzinga.com/markets/cannabis/24/09/40720303/hollywood-star-jim-belushi-brings-cannabis-expertise-to-chicago-conference-in-october">the cannabis sector.</a>
The actor said "It's been a great journey" going from one farm to now having products sold in 14 states.
Cannabis is like acting, Belushi told the crowd.
Belushi said as an actor he asked himself why he was doing acting and it came down to the idea of making people feel good.
"You want them to leave the theater feeling good," Belushi said.
Belushi said the switch to cannabis comes with the same mentality.
"Adding on cannabis to my purpose, the purpose is the same. Cannabis makes people feel good."
The actor and cannabis entrepreneur said cannabis can help with pain, increase happiness and make people feel better overall. "I feel like I am totally on purpose from actor to cannabis," he said.
Belushi, who stars in "Growing Belushi," which airs on Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)-owned Discovery, credits his partners and relationships in the industry for helping his growth.
"We are bred on a plant that is based on kindness, generosity and healing."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41233018/exclusive-ross-gerber-sees-tsunami-of-money-pouring-into-cannabis-companies-upon-federal-legaliz">EXCLUSIVE: Ross Gerber Sees &#8216;Tsunami Of Money&#8217; Pouring Into Cannabis Companies Upon Federal Legalization, Says Cannabis Is One Of &#8216;Biggest&#8217; Opportunities Beyond AI</a>
Challenges of Cannabis: Belushi said one of the main differences between cannabis and "show business" is the amount of time it takes to get things done.
Within the cannabis industry, the biggest challenge Belushi highlighted was the price. "Growing is very expensive," Belushi said.
The actor and entrepreneur said the market is oversaturated and it's hard to make any margin in states like Oregon.
Asked later on about his advice to someone looking to start their own grow farm, Belushi answered, "Don't do it. Don't f&#x2A;&#x2A;&#x2A;ing do it."
Belushi admitted he never got involved in cannabis for the money and was just hoping to break even, adding "I already got my TV money."
Belushi said he got involved in cannabis and remains involved despite the struggles as people should focus on things they're passionate about.
"I have passion for what this plant can bring to our community."
 What's Next: Belushi said he was excited about the potential for rescheduling happening this year and questions why it hasn't happened.
Until rescheduling happens, Belushi said doctors at Veteran Affairs can't give people cannabis instead of oxycontin.
"Why aren't we taking care of them?" Belushi asked of the country's veterans.
Belushi also said he was disappointed to see Vice President Kamala Harris talk about putting so many people in California into jail when many were put in there for marijuana-related crimes. The actor noted that he is not anti-Harris, but disagrees in this matter.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41241368/exclusive-elon-musks-x-is-safe-space-to-say-weed-the-only-social-platform-where-you-can-talk-abo">EXCLUSIVE: Elon Musk&#8217;s X Is &#8216;Safe Space&#8217; To Say Weed: &#8216;The Only Social Platform Where You Can Talk About Cannabis Openly&#8217;</a></li>
</ul>
Photo: Jim Belushi at the Benzinga Cannabis Conference 2024, Photo by Wendy Davis

Cannabis

Entertainment

Events

Exclusives

Jim Belushi Compares Passion For Acting To Cannabis Business: 'Makes People Feel Good'

UBS analyst Trung Huynh maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral and raises the price target from $50 to $54.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $54

UBS analyst Colin Bristow maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and lowers the price target from $142 to $136.

UBS Maintains Buy on Merck & Co, Lowers Price Target to $136

UBS analyst Navin Jacob maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Neutral and raises the price target from $185 to $195.

ABBV

UBS Maintains Neutral on AbbVie, Raises Price Target to $195

UBS analyst Jay Sole maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy and raises the price target from $225 to $226.

DECK

UBS Maintains Buy on Deckers Outdoor, Raises Price Target to $226

UBS analyst Dennis Geiger maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Buy and raises the price target from $305 to $345.

UBS Maintains Buy on McDonald's, Raises Price Target to $345

Citigroup analyst Christopher Allen maintains Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) with a Buy and raises the price target from $32 to $37.

VIRT

Citigroup Maintains Buy on Virtu Finl, Raises Price Target to $37

Citigroup analyst Thomas Palmer maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Buy and raises the price target from $79 to $80.

MDLZ

Citigroup Maintains Buy on Mondelez International, Raises Price Target to $80

Following the Arrangement, BIPC shareholders will own an economically equivalent security that provides the same economic benefits and governance of investing in our company today. The Arrangement is also expected to be tax-deferred for the vast majority of investors, including Canadian and U.S. shareholders.

BIPC

Brookfield Infrastructure Partners, Brookfield Infrastructure Reveal Intention To Complete Reorganization

As the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference </a>came to a close on Wednesday, attendees were treated to the announcement of the winners of the 2024 Benzinga Hemp Beverage Competition. This year's awards showcased the top D9 THC-infused beverages in various categories, celebrating innovation and craftsmanship in cannabis beverages. 
Here's a look at the standout products that took home the top honors.
<h3 class="wp-block-heading">Best D9 THC-Infused Tonic/Elixir</h3>
Winner: Drink Brez D9 THC-Infused Lemon Elderflower Tonic. 
Known for its harmonious blend of THC, CBD, and Lion&#8217;s Mane, Drink Brez promotes a more approachable experience for consumers. Described as delivering "brighter colors, louder laughs, and tastier snacks," the tonic is gaining popularity for being a no-hangover alternative to alcohol, combining organic ingredients with federally legal THC.
Runner-up: Forward Beverage Co. D9 THC-Infused In-Fashioned Social Seltzer. 
Forward Beverage Co. earned runner-up with its In-Fashioned Social Seltzer, which emphasizes providing alternatives to alcohol. This beverage, crafted to be savored socially, has been making waves in Wisconsin as a non-alcoholic option that doesn't leave anyone feeling left out.
<h3 class="wp-block-heading">Best D9 THC-Infused Soda</h3>
Winner: Mary Jones D9 THC-Infused Root Beer. 
Mary Jones continued its legacy of crafting sodas with an extra kick by taking the top spot in the D9 THC-infused soda category. With a reputation for delivering exceptional flavors since 1996, Mary Jones' Root Beer is infused with cannabis while maintaining the same "best damn cane sugar soda" standards the company is known for.
Runner-up: Mary Jones D9 THC-Infused Berry Lemonade Soda. 
Mary Jones&#8217;s Berry Lemonade Soda also earned accolades, securing runner-up in this category. Known for its bold flavors, this soda is another testament to the company's commitment to innovation and customer satisfaction.
Also Read: <a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a>
<h3 class="wp-block-heading">Best D9 THC-Infused Seltzer</h3>
Winner: Share D9 THC-Infused Cucumber &amp; Lime Seltzer. 
Share took the top prize in the seltzer category with their refreshing Cucumber &amp; Lime Seltzer. This beverage is produced with an emphasis on excellence, from "seed to table," ensuring quality cannabis is used in every sip.
Runner-up: Wynk D9 THC-Infused Juicy Mango Seltzer. 
Wynk's Juicy Mango Seltzer claimed the runner-up position, winning over judges with its promise of consistency and balance. Wynk prides itself on delivering an exact dose with each can, allowing consumers to enjoy a reliably social experience.
<h3 class="wp-block-heading">Best D9 THC-Infused RTD (Ready to Drink)</h3>
Winner: Better Than Booze D9 THC-Infused Rosemary Grapefruit Paloma. 
Better Than Booze took the spotlight in the RTD category with their Rosemary Grapefruit Paloma. Co-founded by Drea Groeschel, this beverage provides a refreshing alternative to traditional alcoholic cocktails. Inspired by the desire to "swap out regular wine for a better alternative," the drink replicates classic cocktail flavors without the hangover.
Runner-up: Howdy D9 THC-Infused Paloma. 
Howdy's Texas-born D9 THC-infused Paloma earned the runner-up award with its Cosmic Cowboy branding and focus on low-dose, fast-acting beverages. Known for being &#8216;best-served cold and enjoyed socially,&#8217; Howdy is gaining a reputation for making cannabis-infused drinks that are both effective and enjoyable.
<h3 class="wp-block-heading">Best D9 THC-Infused Coffee/Tea</h3>
Winner: Howdy D9 THC-Infused Sweet Tea.
Howdy returned to the winner's circle, taking the top prize in the D9 THC-infused coffee/tea category with their Sweet Tea. A smooth blend of classic Southern flavors infused with THC, this drink is redefining what tea can be.
Runner-up: Squoze D9 THC-Infused Ahhhnold Kush Tea &amp; Lemonade.
Squoze secured the runner-up award with their Ahhhnold Kush Tea &amp; Lemonade. Known for being "squoze from fresh fruit," Squoze is making a name for itself by infusing traditional beverages with bold, cannabis-infused twists.
With the Benzinga Cannabis Capital Conference now concluded, these award-winning beverages continue to shine as leaders in the growing THC-infused beverage market. Look out for more insights and innovations from the cannabis industry's top players.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41259102/exclusive-cannabis-tech-leaders-push-personalization-data-insights-as-key-to-beating-price-wars">EXCLUSIVE: Cannabis Tech Leaders Push Personalization, Data Insights As Key To Beating Price Wars</a></li>
</ul>
Photo by Wendy Davis.

Benzinga Cannabis Capital Conference Celebrates Best D9 THC Beverages Of 2024

The&nbsp;$0.27&nbsp;per share quarterly cash dividend will be paid on&nbsp;January 8, 2025, to stockholders of record on&nbsp;December 13, 2024.&nbsp;

Dividends

AVNT

Avient Boosts Annual Dividend By 5% From $1.03 To $1.08 Per Share

Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) shares traded higher on heavy volume Wednesday after marking a new 52-week low on Tuesday. Here's a <a href="https://www.benzinga.com/news/24/10/41216891/celsius-holdings-stock-hit-52-week-lows-on-monday-whats-going-on">look at what's going on.&nbsp;</a>
What To Know: Celsius Holdings shares climbed Wednesday despite a lack of company-specific news. The stock has become a favorite among retail investors and chatter on social media revolved around the stock reaching key support levels and bouncing higher.&nbsp;
Celsius shares reached a 52-week high of $99.62 back in March and have fallen more than 60% over the past six months, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
Read Next: <a href="https://www.benzinga.com/fintech/24/10/41234302/whats-going-on-with-sofi-stock">What&#8217;s Going On With SoFi Stock?</a>
The sell-off in Celsius shares accelerated in September after the company said PepsiCo was scaling back orders to <a href="https://www.benzinga.com/news/24/09/40733143/whats-going-on-with-celsius-holdings-stock">optimize its inventory</a>. Celsius said it expected its distribution partner to reduce orders by about $100 million.
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Celsius shares are trading above the stock&#8217;s 50-day moving average of $36.23 and slightly above its 52-week low of $28.20.&nbsp;
<h1 class="wp-block-heading">CELH Stock Prediction 2024</h1>
When buying a stock for a longer time horizon, it is important for investors to assess where they think the stock is headed in the future.
When mapping a stock's future trajectory, investors should consider factors including future earnings expectations and expected performance against a benchmark.
Celsius Holdings&#8217; revenue has grown at an average rate of 98.52% annually over the past five years. The average one-year price target from analysts is $53.64, representing an expected 75.81% upside in 2025.
While past performance is not a guarantee of future results, investors should also look at a stock's historical performance when compared to both a benchmark index and the company's peers. Shares of Celsius Holdings have seen an annualized return of -3.06%, underperforming the S&amp;P500 index by 12.72%. This compares to 7.79% growth in the overall Consumer Staples sector. Celsius Holdings has a beta of 0.92.
CELH Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Celsius Holdings shares are up 3.57% after-hours at $31.60 after climbing 6.16% in regular trading Wednesday.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41217379/google-must-open-play-store-to-competitors-judge-orders">Google Must Open Play Store To Competitors, Judge Orders</a></li>
</ul>
Photo: Courtesy of Celsius Holdings, Inc.

After-Hours Center

Movers

CELH

What Happened With Celsius Holdings Stock Today?

Citigroup analyst Thomas Palmer maintains Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) with a Neutral and lowers the price target from $63 to $60.

Citigroup Maintains Neutral on Tyson Foods, Lowers Price Target to $60

&#8220;Discounts will hurt your margins, but loyalty points won't," said Lisa Williams, founder of The Toke Agency, at <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga&#8217;s Cannabis Capital Conference on Oct. 9. </a>
Williams was one of several experts discussing how cannabis retailers can use data to not only improve margins but also strengthen customer retention. 
The panel, titled &#8220;Maximizing Margins: Leveraging Data for Effective Cannabis Retail Pricing and E-commerce Strategies,&#8221; was moderated by Debra Borchardt, co-founder of Green Market Report.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41259102/exclusive-cannabis-tech-leaders-push-personalization-data-insights-as-key-to-beating-price-wars">EXCLUSIVE: Cannabis Tech Leaders Push Personalization, Data Insights As Key To Beating Price Wars</a>
Williams said that the real key to maintaining margins in cannabis retail isn't slashing prices — it's using data to build loyalty. By offering perks such as points or exclusive access to events, dispensaries can entice customers to come back. 
"How you build loyalty is you give them rewards for keeping them," Williams noted. 
Williams' point was simple: build a brand that encourages loyalty rather than price-driven shopping.
<h1 class="wp-block-heading">Turning Messy Data Into Actionable Insights</h1>
Kris Walker, co-founder of Hoodie Analytics, took the conversation deeper into how data can drive better decisions.
 "The trick is not just collecting data — it's making sure you have the processes in place to leverage it," Walker said. His company provides retailers with real-time data that pulls from multiple sources, including POS systems and wholesale platforms.
What Walker wanted to make clear was that data on its own doesn't solve problems. Retailers need to know how to use it. "We take messy data and turn it into something operators can use to grow their businesses," he added. 
Whether it's pricing strategies, product assortment, or even timing sales, the right data can guide retailers to make smarter choices, allowing them to adapt to fast-moving market trends.
<h1 class="wp-block-heading">Combining Data Sources For A Full Picture</h1>
Jackie Gonzalez-Becerra, vice president of revenue at Weedmaps, echoed the need for retailers to take data seriously — but stressed that internal data isn't enough.
"It's not enough to just look at your sales. You need to bring in external data — whether it's from Hoodie, Headset or BDS — to get a complete view of what's happening in the market," she said.
Gonzalez-Becerra explained how Weedmaps works with dispensaries to help them integrate 17 years of consumer shopping data into their operations.
This kind of deep data integration can reveal market trends that retailers wouldn't otherwise see. With the holiday season coming up, she pointed out how critical it is to start planning promotions early and anticipate consumer behavior changes.
<h1 class="wp-block-heading">Proactive Planning with Data: Fluent's Strategy</h1>
Robert Beasley, CEO of Fluent, brought in a real-world example of how data helped his company stay competitive in Florida. Back in 2022, Fluent forecasted a 20% price compression in the market, forcing them to plan ahead and cut costs. 
"We realized we needed to be 20% more efficient in two years if we wanted to maintain our margins," Beasley said.
Instead of waiting for market conditions to shift and reacting too late, Fluent took a proactive approach. They used data to optimize everything from cultivation to product pricing, staying ahead of the curve rather than playing catch-up. Beasley's message was clear: it's not enough to just respond to market changes — businesses need to see them coming.
<h1 class="wp-block-heading">Creating A Data-Driven Culture</h1>
One of the key takeaways from the panel was the need for a data-driven culture in cannabis businesses. Beasley shared that many cannabis companies still make decisions based on gut feelings or anecdotal evidence. 
"Humans are incapable of making anecdotal decisions on large data sets," he said, pointing out that without the right data and tools, businesses risk missing key trends.
Walker added to this by noting that companies need to ensure their teams are equipped with the right KPIs and data access. "If you don't give your team the tools and accountability they need, data can become overwhelming," Walker said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c">EXCLUSIVE: Cannabis Companies Must &#8216;Get More Juice From The Same Squeeze,&#8217; Says Cresco Labs CEO As Challenges Persist</a></li>
</ul>
Photo: Benzinga Cannabis Capital Conference 2024, photo by Wendy Davis

Markets

EXCLUSIVE: Why Loyalty Programs, Not Discounts, Are The Future Of Cannabis Retail

Citigroup analyst Thomas Palmer maintains Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) with a Buy and lowers the price target from $41 to $39.

Citigroup Maintains Buy on Kraft Heinz, Lowers Price Target to $39

Citigroup analyst James Hardiman maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Buy and raises the price target from $25 to $28.

Citigroup Maintains Buy on Carnival, Raises Price Target to $28

Guidance

BSET

Bassett Says Made Progress On Restructuring Plan Announced In July, On Target To Improve Bottom-line Between $5.5M And $6.5M On Annual Basis

Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) has outperformed the market over the past 10 years by 3.05% on an annualized basis producing an average annual return of 14.93%. Currently, Sprouts Farmers Market has a market capitalization of $11.39 billion. 
Buying $1000 In SFM: If an investor had bought $1000 of SFM stock 10 years ago, it would be worth $4,153.28 today based on a price of $113.80 for SFM at the time of writing.
<h3>Sprouts Farmers Market's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728509416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Sprouts Farmers Market Stock In The Last 10 Years

Bassett Furniture Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSET#NASDAQ">BSET</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.38) by 36.84 percent. This is a 73.33 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $75.62 million which missed the analyst consensus estimate of $80.07 million by 5.56 percent. This is a 13.30 percent decrease over sales of $87.22 million the same period last year.

Earnings

Earnings Misses

Bassett Furniture Indus Q3 2024 GAAP EPS $(0.52) Misses $(0.38) Estimate, Sales $75.62M Miss $80.07M Estimate

Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 20 years by 4.33% on an annualized basis producing an average annual return of 12.88%. Currently, Progressive has a market capitalization of $146.89 billion. 
Buying $1000 In PGR: If an investor had bought $1000 of PGR stock 20 years ago, it would be worth $11,603.89 today based on a price of $250.76 for PGR at the time of writing.
<h3>Progressive's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728509411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Progressive Stock In The Last 20 Years

Theratechnologies (TSE:TH) has released an update. At the Theratechnologies Annual Meeting of Shareholders held online on May 9, 2024, all eight di...

Theratechnologies Shareholders Elect Directors, Appoint Auditors

JonesTrading analyst Justin Walsh reiterated a Buy rating on Theratechnologies (THTX – Research Report) today and set a price target of $3.00. The ...

Theratechnologies (THTX) Gets a Buy from JonesTrading

Theratechnologies reports Q2 results

Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Theratechnologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/thtx-stock-quote/">THTX</a>) just reported results for the second quarter of 2024.<ul><li>Theratechnologies reported earnings per share of 2 cents. This was above the analyst estimate for EPS of -2 cents.</li><li>The company reported revenue of $22.02 million.</li><li>This was 1.41% better than the analyst estimate for revenue of $21.71 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/07/thtx-stock-earnings-theratechnologies-for-q2-of-2024/">THTX Stock Earnings: Theratechnologies Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

THTX Stock Earnings: Theratechnologies Beats EPS, Beats Revenue for Q2 2024

Theratechnologies (THTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from ...

Theratechnologies: Strong Q2 Performance and Positive Outlook Justify Buy Rating

The healthcare industry is growing massively owing to new drugs and technological innovations. Thus, investing in fundamentally robust small-cap stocks Theratechnologies (THTX), Anika Therapeutics. (ANIK), and SIGA Technologies (SIGA) could be a good idea. Read more to find out… The healthcare industry plays a major economic role by providing essential products and services that enhance people's health and well-being. Recent years have brought significant changes to the sector, driven by technological advancements, personalized healthcare, and biotechnological innovations.
Amid this, it could be wise to invest in fundamentally sound small-cap healthcare stocks Theratechnologies (<a href="https://stocknews.com/stock/THTX/">THTX</a>), Anika Therapeutics (<a href="https://stocknews.com/stock/ANIK/">ANIK</a>), and SIGA Technologies (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>). With a market capitalization of <a href="https://www.investopedia.com/terms/s/small-cap.asp">up to $2 billion</a>, these companies offer greater growth potential than large-cap firms and could be valuable additions to one's portfolio.
Over the last decade, significant advancements in survival rates and patient quality of life have greatly benefited the healthcare industry. These improvements stem from the intersection of medical and technological breakthroughs, which have enhanced the effectiveness of healthcare delivery and treatment outcomes.
Integrating high-tech diagnostic and therapeutic equipment with clinical practices has significantly improved healthcare outcomes. Innovations such as telemedicine, robotic process automation, and remote patient monitoring are <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10993086/">transforming patient care</a> by making it more efficient and accessible, benefiting the sector.
The continuous introduction of new drugs also benefits the industry by expanding treatment options and improving patient care. The U.S. Food and Drug Administration's <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approval of 23 new drugs</a> this year for various chronic conditions illustrates the sector's growth potential and capacity to advance medical treatments.
According to a report by Precedence Research, the global biotechnology market is expected to grow at <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20U.S.%20biotechnology%20market%20size%20was%20valued%20at,a%20CAGR%20of%2011.90%25%20from%202024%20to%202033.">a CAGR of 11.8%</a>, reaching approximately $4.25 trillion by 2033. This growth signifies increased investment and innovation, driving further advancements and improvements in patient care.
Considering these factors, let's explore the fundamentals of three promising small-cap healthcare stocks, starting with #3.
Stock #3: Theratechnologies Inc. (<a href="https://stocknews.com/stock/THTX/">THTX</a>)
THTX, based in Montreal, Canada, has a market capitalization of $62.76 million and develops therapies that address unmet medical needs. Its pipeline includes the F8 Formulation in Phase 2b/3 trials for tesamorelin in treating nonalcoholic steatohepatitis, a multi-dose pen injector for tesamorelin administration, and more.
On May 23, THTX reported <a href="https://www.theratech.com/news-releases/news-release-details/theratechnologies-sudocetaxel-zendusortide-asco-2024">Phase 1 data</a> for its investigational peptide drug conjugate, sudocetaxel zendusortide (TH1902). The data showcased promising long-term efficacy and a manageable safety profile in patients with solid tumors, highlighting the potential of TH1902 in advancing cancer treatment.
This could position THTX favorably for future development stages and regulatory approval.
On April 8, THTX showcased preclinical data <a href="https://www.theratech.com/news-releases/news-release-details/theratechnologies-preclinical-data-presentation-aacr-2024">demonstrating the versatility</a> of its SORT1+ Technology&#x2122; platform. The data revealed that camptothecin-peptide conjugates effectively regress tumors in colorectal cancer (CRC) and triple-negative breast cancer (TNBC) models.
The validation could boost THTX's growth by confirming the platform's broad application and efficacy. The promising results could attract potential partners and investors, positioning THTX as a leader in innovative cancer treatments and accelerating its path to clinical development and market success.
For the fiscal 2024 second quarter that ended May 31, 2024, THTX reported revenue of $22.02 million, indicating a 25.5% year-over-year increase. Its profit from operating activities was $3.29 million compared to a loss of $7.94 million in the previous year's quarter.
Moreover, the company reported a <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> and income per share of $987 thousand and $0.02, compared to a loss and loss per share of $10.01 million and $0.41 in the prior year's period.
Street expects THTX's revenue to rise 15.2% year-over-year to $23.94 million in the fiscal 2024 third quarter ending in August. The company's EPS is expected to be $0.04. Moreover, THTX has surpassed the consensus EPS estimates in three of the four trailing quarters.
Shares of THTX have gained 8.3% over the past three months and 1.11% over the past nine months to close the last trading session at $1.37.
THTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system. The POWR Ratings are calculated considering 118 different factors, each weighted optimally.
THTX stock has an A grade for Growth and a B for Value and Sentiment. It is ranked #27 in the 639-stock <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
Beyond what is stated above, we've also rated THTX for Quality, Momentum, and Stability. <a href="https://stocknews.com/stock/THTX/">Click here</a> to get all THTX ratings.
Stock #2: Anika Therapeutics, Inc. (<a href="https://stocknews.com/stock/ANIK/">ANIK</a>)
Valued at $374.21 million, ANIK is a joint preservation company that develops and markets products using hyaluronic acid technology. Its product family includes Monovisc and Orthovisc for pain management, joint preservation solutions like Integrity and Hyalofast, Arthrosurface for sports medicine, and non-orthopedic products like adhesion barrier and wound care.
On July 11, ANIK announced <a href="https://ir.anika.com/Anika-Announces-Full-Market-Release-of-the-Integrity-TM-Implant-System,-a-Regenerative-Hyaluronic-Acid-Based-Scaffold-for-Rotator-Cuff-and-Other-Tendon-Repairs">a full market release</a> of its Integrity Implant System across the United States. The Integrity System includes a hyaluronic acid-based implant with bone and tendon fixation components and ingenious one-time use arthroscopic delivery instruments and is made to protect an injured tendon and propagate healing in rotator cuff repair and other tendon procedures
The positive feedback from the limited release underscores Integrity's clear advantages over collagen patches. Initially focused on rotator cuff repairs, Integrity's versatility has been proven in diverse applications, including Achilles tendon and foot repairs. This breakthrough positions ANIK as a leader in advancing surgical outcomes, driving its growth and reputation.
For the fiscal 2024 second quarter, which ended June 30, 2024, ANIK reported revenue of $41.92 million. The company's adjusted gross profit amounted to $27.52 million, while it registered an adjusted EBITDA of $6.29 million, indicating a marginal year-over-year increase.
Furthermore, ANIK's income from operations amounted to $161 thousand compared to a loss of $3.63 million in the previous year's quarter.
Analysts predict ANIK's revenue for the fiscal fourth quarter ending December 2024 to increase 5.8% year-over-year to $45.45 million. Its EPS for the same quarter is expected to grow 530% from the prior year's quarter to $0.32.  Moreover, the company surpassed consensus revenue estimates in all four trailing quarters.
The stock has gained 7.2% over the past six months and 20% over the past nine months to close the last trading session at $25.29.
ANIK's robust fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
ANIK has a B Growth and Stability. It is ranked #23 out of 639 stocks in the Biotech industry.
In addition to the POWR Ratings we've stated above, we also have ANIK ratings for Momentum, Value, Sentiment, and Quality. Get all ANIK ratings <a href="https://stocknews.com/stock/ANIK/">here</a>.
Stock #1: SIGA Technologies, Inc. (<a href="https://stocknews.com/stock/SIGA/">SIGA</a>)
With a market capitalization of $854.29 million, SIGA is a commercial-stage pharmaceutical firm focused on health security, including countermeasures for biological, chemical, radiological, and nuclear threats. Its lead product, TPOXX, is an antiviral drug available in oral and IV forms for treating human smallpox disease.
On July 19, SIGA announced that the U.S. Department of Health and Human Services had exercised <a href="https://investor.siga.com/investors/news/news-details/2024/SIGA-Announces-U.S.-Government-Procurement-Order-of-113-Million-for-Oral-TPOXX/default.aspx">a $113 million procurement option</a> for oral TPOXX&#xAE; treatment courses. The substantial order builds on 2023's orders from the U.S. government and 15 international customers.
The consistent support from government and international customers could enhance SIGA's market position and credibility, paving the way for continued innovation and readiness against biological threats.
On June 17, SIGA announced an agreement to <a href="https://investor.siga.com/investors/news/news-details/2024/SIGA-Announces-Agreement-to-Sell-TPOXX-to-ASEAN-Member-States-06-17-2024/default.aspx">expand access to TPOXX (tecovirimat)</a> across the ASEAN member states, a political and economic union in Southeast Asia. The agreement would help SIGA establish a presence in a densely populated area and lay the foundation for future developments.
SIGA's total revenue for the fiscal 2024 second quarter, which ended June 30, 2024, amounted to $21.81 million, showing a 270.9% year-over-year growth. The company's net income and EPS were $1.83 million or $0,03 per share, compared to a loss of $2.87 million and $0.04 in the previous year's quarter.
SIGA's revenue and EPS for the fiscal year ending December 2024 are expected to increase 14.7% and 6.3% year-over-year to $160.46 million and $1.01, respectively.
The stock has gained 52.5% over the past three months and 142.3% over the past nine months to close the last trading session at $11.97.
SIGA's positive fundamentals are mirrored in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
SIGA has an A grade for Value and Quality and a B for Growth. It is ranked #14 out of 362 stocks in the Biotech industry.
Beyond what we stated above, we also have given SIGA grades for Momentum, Stability, and Sentiment. Get all the SIGA ratings <a href="https://stocknews.com/stock/SIGA/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;

<hr />
SIGA shares fell $11.97 (-100.00%) in premarket trading Thursday. Year-to-date, SIGA has gained 113.75%, versus a 15.12% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/siga-anik-thtx-3-small-cap-healthcare-stocks-with-breakthrough-potential/>3 Small-Cap Healthcare Stocks With Breakthrough Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Healthcare Stocks With Breakthrough Potential

Theratechnologies (TSE:TH) has released an update. Theratechnologies has announced a potential early 2025 supply disruption for EGRIFTA SV due to a...

Theratechnologies Faces EGRIFTA SV Supply Disruption

Theratechnologies (TSE:TH) has released an update. Theratechnologies Inc. faces a potential early 2025 supply disruption for its EGRIFTA SV product...

Theratechnologies Braces for Supply Disruption

ANIK

SIGA

THTX

Management

Press Releases

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

Health Care

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Comments

Theratechnologies

Intérêt court

Theratechnologies (NASDAQ:THTX) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL